Teva Presents First Real-World Data from the IMPACT-TD Regis

Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia including social, psychological, physical and recreational aspects of daily living



Data highlight for...

Related Keywords

Nevada , United States , Michigan , Richard Jackson , Las Vegas , Eric Hughes , Drug Administration , Abnormal Involuntary Movement Scale , National Alliance On Mental Illness , Psych Congress Elevate Annual Meeting , Teva Pharmaceutical Industries Ltd , Teva Pharmaceuticals , Psych Congress Elevate , Teva Pharmaceutical Industries , Congress Elevate Annual Meeting , Executive Vice President , Chief Medical Officer , Clinical Global Impression , Reported Outcome , Assistant Clinical Adjunct Professor , Michigan School , Tardive Dyskinesia , Release Tablets , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Pharmaceutical Industries , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Nova Science , From Phenomenology , Mental Illness ,